Mon, November 6, 2023

Serge Belanger Maintained (ARQT) at Strong Buy with Decreased Target to $8 on, Nov 6th, 2023

Serge Belanger of HC Wainwright & Co., Maintained "Arcutis Biotherapeutics, Inc." (ARQT) at Strong Buy with Decreased Target from $22 to $8 on, Nov 6th, 2023.

Serge has made no other calls on ARQT in the last 4 months.



There are 4 other peers that have a rating on ARQT. Out of the 4 peers that are also analyzing ARQT, 2 agree with Serge's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Uy Ear of "Mizuho" Downgraded from Strong Buy to Hold and Decreased Target to $4 on, Friday, October 27th, 2023
  • Jonathan Block of "Goldman Sachs" Downgraded from Strong Buy to Hold and Decreased Target to $6 on, Friday, October 13th, 2023


These are the ratings of the 2 analyists that currently disagree with Serge


  • Louise Chen of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $50 on, Tuesday, August 22nd, 2023
  • Ken Cacciatore of "TD Cowen" Maintained at Buy with Decreased Target to $50 on, Wednesday, August 9th, 2023